UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

 

 

Seres Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.001

(Title of Class of Securities)

81750R102

(CUSIP Number)

Nestlé S.A.

Avenue Nestlé, 55

1800 Vevey

Switzerland

Attention: General Counsel Corporate

Facsimile: 01-41-21-924-2821

with a copy to:

David A. Carpenter, Esq.

Mayer Brown, LLP

1221 Avenue of the Americas

New York, New York 10020

(212) 506-2195

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

August 17, 2020

(Date of Event which Requires Filing of this Statement)

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

 

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

 

 

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section of the Exchange Act but shall be subject to all other provisions of the Exchange Act (however, see the Notes).

 

 

 


CUSIP No. 81750R102

 

  1.    

  Name of Reporting Person

 

  Nestle Health Science US Holdings, Inc. (1)

  2.    

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☐

 

  3.    

  SEC Use Only:

 

  4.    

  Source of Funds (See Instructions):

 

  AF

  5.    

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e):

 

  ☐

  6.    

  Citizenship or Place of Organization:

 

  Delaware

Number of

Shares

  Beneficially  

Owned by

Each

Reporting

Person

With

    7.     

  Sole Voting Power:

 

  0

  8.     

  Shared Voting Power:

 

  6,888,888

  9.     

  Sole Dispositive Power:

 

  0

  10.     

  Shared Dispositive Power:

 

  6,888,888

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person:

 

  6,888,888

12.    

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares: (See Instructions)

 

  ☐

13.    

  Percent of Class Represented by Amount in Row (11):

 

  7.7%

14.    

  Type of Reporting Person (See Instructions):

 

  CO

 

(1) 

Based upon a total of 89,292,533 shares of Common Stock outstanding as of August 17, 2020, as reported by the Issuer in a prospectus supplement (File No. 333-244401) filed with the Securities and Exchange Commission on August 14, 2020 after the closing of the offering and concurrent placement as reported by the Issuer in a free writing prospectus filed with the Securities and Exchange Commission on August 17, 2020

 

2


CUSIP No. 81750R102

 

  1.    

  Name of Reporting Person

 

  NIMCO US, Inc. (1)

  2.    

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☐

 

  3.    

  SEC Use Only:

 

  4.    

  Source of Funds (See Instructions):

 

  AF

  5.    

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e):

 

  ☐

  6.    

  Citizenship or Place of Organization:

 

  Delaware

Number of

Shares

  Beneficially  

Owned by

Each

Reporting

Person

With

    7.     

  Sole Voting Power:

 

  0

  8.     

  Shared Voting Power:

 

  6,888,888

  9.     

  Sole Dispositive Power:

 

  0

  10.     

  Shared Dispositive Power:

 

  6,888,888

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person:

 

  6,888,888

12.    

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares: (See Instructions)

 

  ☐

13.    

  Percent of Class Represented by Amount in Row (11):

 

  7.7%

14.    

  Type of Reporting Person (See Instructions):

 

  CO

 

(1) 

Based upon a total of 89,292,533 shares of Common Stock outstanding as of August 17, 2020, as reported by the Issuer in a prospectus supplement (File No. 333-244401) filed with the Securities and Exchange Commission on August 14, 2020 after the closing of the offering and concurrent placement as reported by the Issuer in a free writing prospectus filed with the Securities and Exchange Commission on August 17, 2020.

 

3


CUSIP No. 81750R102

 

  1.    

  Name of Reporting Person

 

  Nestlé S.A.

  2.    

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☐

 

  3.    

  SEC Use Only:

 

  4.    

  Source of Funds (See Instructions):

 

  AF

  5.    

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e):

 

  ☐

  6.    

  Citizenship or Place of Organization:

 

  Switzerland

Number of

Shares

  Beneficially  

Owned by

Each

Reporting

Person

With

    7.     

  Sole Voting Power:

 

  0

  8.     

  Shared Voting Power:

 

  7,892,890

  9.     

  Sole Dispositive Power:

 

  0

  10.     

  Shared Dispositive Power:

 

  7,892,890

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person:

 

  7,892,890

12.    

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares: (See Instructions)

 

  ☐

13.    

  Percent of Class Represented by Amount in Row (11):

 

  8.8%(1)

14.    

  Type of Reporting Person (See Instructions):

 

  CO

 

(1) 

Based upon a total of 89,292,533 shares of Common Stock outstanding as of August 17, 2020, as reported by the Issuer in a prospectus supplement (File No. 333-244401) filed with the Securities and Exchange Commission on August 14, 2020 after the closing of the offering and concurrent placement as reported by the Issuer in a free writing prospectus filed with the Securities and Exchange Commission on August 17, 2020.


CUSIP No. 81750R102

 

  1.    

  Name of Reporting Person

 

  Nestlé US Holdco, Inc. (1)

  2.    

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☐

 

  3.    

  SEC Use Only:

 

  4.    

  Source of Funds (See Instructions):

 

  AF

  5.    

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e):

 

  ☐

  6.    

  Citizenship or Place of Organization:

 

  Delaware

Number of

Shares

  Beneficially  

Owned by

Each

Reporting

Person

With

    7.     

  Sole Voting Power:

 

  6,888,888

  8.     

  Shared Voting Power:

 

  0

  9.     

  Sole Dispositive Power:

 

  6,888,888

  10.     

  Shared Dispositive Power:

 

  0

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person:

 

  6,888,888

12.    

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares: (See Instructions)

 

  ☐

13.    

  Percent of Class Represented by Amount in Row (11):

 

  7.7%

14.    

  Type of Reporting Person (See Instructions):

 

  CO

 

(1) 

Based upon a total of 89,292,533 shares of Common Stock outstanding as of August 17, 2020, as reported by the Issuer in a prospectus supplement (File No. 333-244401) filed with the Securities and Exchange Commission on August 14, 2020 after the closing of the offering and concurrent placement as reported by the Issuer in a free writing prospectus filed with the Securities and Exchange Commission on August 17, 2020.

 

5


CUSIP No. 81750R102

 

  1.    

  Name of Reporting Person

 

  Société des Produits Nestlé S.A.

  2.    

  Check the Appropriate Box if a Member of a Group (See Instructions)

  (a)  ☐        (b)  ☐

 

  3.    

  SEC Use Only:

 

  4.    

  Source of Funds (See Instructions):

 

  AF

  5.    

  Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e):

 

  ☐

  6.    

  Citizenship or Place of Organization:

 

  Switzerland

Number of

Shares

  Beneficially  

Owned by

Each

Reporting

Person

With

    7.     

  Sole Voting Power:

 

  0

  8.     

  Shared Voting Power:

 

  7,847,890

  9.     

  Sole Dispositive Power:

 

  0

  10.     

  Shared Dispositive Power:

 

  7,847,890

11.    

  Aggregate Amount Beneficially Owned by Each Reporting Person:

 

  7,847,890

12.    

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares: (See Instructions)

 

  ☐

13.    

  Percent of Class Represented by Amount in Row (11):

 

  8.8%(1)

14.    

  Type of Reporting Person (See Instructions):

 

  CO

 

(1) 

Based upon a total of 89,292,533 shares of Common Stock outstanding as of August 17, 2020, as reported by the Issuer in a prospectus supplement (File No. 333-244401) filed with the Securities and Exchange Commission on August 14, 2020 after the closing of the offering and concurrent placement as reported by the Issuer in a free writing prospectus filed with the Securities and Exchange Commission on August 17, 2020.

 

6


SCHEDULE 13D

Explanatory Note

Pursuant to Rule 13d-2 of the Securities Exchange Act of 1934, as amended, this Amendment No. 1 (this “Amendment”) amends and supplements certain items of the Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on April 11, 2018, (the “Original Schedule 13D”), by the Reporting Persons relating to the Common Stock of Seres Therapeutics, Inc. (the “Issuer”). This Amendment amends the Original Schedule 13D on behalf of the Reporting Persons to furnish the information set forth herein. Except as set forth below, all Items of the Original Schedule 13D remain unchanged. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Original Schedule 13D. Following an internal reorganization completed in 2019, two additional legal entities, Société des Produits Nestlé S.A., a Swiss société anonyme (“SPN”) and Nestlé US Holdco, Inc., a Delaware corporation (“Nestlé US Holdco”), were added to the beneficial ownership chain. Accordingly, the Original Schedule 13D is amended by this Amendment to add these two entities as Reporting Persons.

Item 3. Source and Amount of Funds or Other Consideration

Item 3 of the Original Schedule 13D is hereby amended and supplemented to include the following:

On August 12, 2020, SPN entered into a Securities Purchase Agreement dated August 12, 2020, between the Issuer and SPN (the “2020 Purchase Agreement”), pursuant to which SPN purchased 959,002 newly issued shares of the Issuer’s Common Stock at a cash purchase price of $20.855 per share for an aggregate purchase price of $19,999,986.71. SPN purchased these shares with funds from its working capital. The 2020 Purchase Agreement is incorporated herein by reference as described in Item 6 below.

Item 4. Purpose of Transaction

Item 4 of the Original Schedule 13D is hereby amended and restated as follows:

The Reporting Persons from time to time review their investment in and collaboration with the Issuer. Based on such review and depending on the price and availability of the Issuer’s securities and the terms of the existing agreements between the Reporting Persons and the Issuer, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of the Common Stock or otherwise, they may acquire Common Stock or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Common Stock currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. The Reporting Persons may also propose or take one or more of the actions described in subsections (a) through (j) of Item 4 of Schedule 13D and may discuss such actions with the Issuer and Issuer’s management and the board of directors, other stockholders of the Issuer and other interested parties.

The information in Item 6 of this Amendment is incorporated by reference herein.

Item 5. Interest in Securities of the Issuer

The first paragraph of Item 5(a) – (b) of the Original Schedule 13D is hereby amended and restated as follows:

The information contained on the cover pages to this Amendment is incorporated herein by reference. The 6,888,888 shares of Common Stock reported on this Amendment are directly held by NHS, which is a wholly-owned subsidiary of NIMCO. NIMCO, in turn, is a wholly-owned subsidiary of Nestlé US Holdco, which is a wholly-owned subsidiary of SPN. The ultimate parent company of NHS, NIMCO, Nestlé US Holdco and SPN is

 

1


Nestlé S.A. Based upon information contained in a prospectus supplement (File No. 333-244401) filed with the SEC on August 14, 2020 and a free writing prospectus filed with the SEC on August 17, 2020, the total issued and outstanding shares of Common Stock held by NHS comprises approximately 7.7% of the Issuer’s issued and outstanding Common Stock. The 959,002 shares of Common Stock acquired pursuant to the 2020 Purchase Agreement reported on this Amendment are directly held by SPN, which is a wholly-owned subsidiary of Nestlé S.A. Based upon information contained in a prospectus supplement (File No. 333-244401) filed with the SEC on August 14, 2020 and a free writing prospectus filed with the SEC on August 17, 2020, the total issued and outstanding shares of Common Stock held by SPN comprises approximately 8.8% of the Issuer’s issued and outstanding Common Stock.

Additionally, Grégory Behar, who is listed on Schedule I hereto, has received a grant of options to acquire 45,000 shares of Common Stock, all of which have vested as of the date of this Amendment. Nestlé S.A is the beneficial owner of all options held by Mr. Behar.

Except for the shares of Common Stock owned by NHS and SPN and the options held by Mr. Behar described in this Item 5, none of the Reporting Persons or, to the knowledge of the Reporting Persons, any of the other persons listed on Schedule I hereto beneficially owns any other securities of the Issuer.

(c) Except as described in Item 3, neither the Reporting Persons nor, to the knowledge of the Reporting Persons, any person listed on Schedule I hereto, have effected any transactions in the Common Stock during the past 60 days.

(d) No other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities covered by this Amendment.

(e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

Item 6 of the Original Schedule 13D is hereby amended and supplemented to include the following:

Series D Purchase Agreement

The Standstill Restrictions under the Series D Purchase Agreement have expired and are no longer in effect.

2020 Purchase Agreement

On August 12, 2020, SPN entered into a Securities Purchase Agreement dated August 12, 2020, between the Issuer and SPN, pursuant to which SPN purchased 959,002 newly issued shares of the Issuer’s Common Stock at a cash purchase price of $20.855 per share for an aggregate purchase price of $19,999,986.71. The 2020 Purchase Agreement contained customary representations, warranties and covenants by, among and for the benefit of the parties.

Item 7. Material to be Filed as Exhibits

 

Exhibit 1    Securities Purchase Agreement, dated as of August 12, 2020, between Société des Produits Nestlé S.A. and the Issuer (Incorporated by reference to Exhibit 10.1 to the Issuer’s Current Report on Form 8-K filed on August 14, 2020).
Exhibit 2    Joint Filing Agreement (filed herewith).

 

2


SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated August 19, 2020

 

NESTLE HEALTH SCIENCE US HOLDINGS, INC.
By:  

/s/ James Pepin

  Name: James Pepin
  Title: Director and President
NIMCO US, INC.
By:  

/s/ Dan Nugent

  Name: Dan Nugent
  Title: Chief Legal Officer and General Counsel
NESTLÉ S.A.
By:  

/s/ Gregory Behar

  Name: Gregory Behar
  Title: Deputy Executive Vice President
NESTLÉ US HOLDCO, INC.
By:  

/s/ Michael Prewitt

  Name: Michael Prewitt
  Title: Secretary
SOCIETE DES PRODUITS NESTLE S.A.
By:  

/s/ Claudio Kuoni

  Name: Claudio Kuoni
  Title: Vice President


SCHEDULE I

DIRECTORS AND EXECUTIVE OFFICERS OF NHS,

PERSONS CONTROLLING NHS AND EXECUTIVE OFFICERS AND DIRECTORS OF OTHER

PERSONS IN CONTROL OF NHS

NHS

NHS is a corporation organized under the laws of the State of Delaware with its principal business address at 1812 North Moore Street, Arlington, VA 22209. NHS is a wholly-owned subsidiary of NIMCO. The name, present principal employment and citizenship of each director and executive officer of NHS is set forth below.

 

Name

  

Present Principal Employment

  

Citizenship

1. Claudio Kuoni    Director, NHS    Swiss
2. James Pepin    Director, NHS    US
3. Michael Prewitt    Secretary (non Director), NHS    US
4. Alexandra Neely    Treasurer, NHS    US
5. James Parent    Head of Tax, NHS    US
6. Alan Pasetsky    Vice President, NHS    US

NIMCO

NIMCO is organized under the laws of the State of Delaware with its principal business address at 1812 North Moore Street, Arlington, VA 22209. NIMCO is a wholly-owned subsidiary of Nestlé US Holdco, Inc.. The name, present principal employment and citizenship of each director and executive officer of NIMCO is set forth below.

 

Name

  

Present Principal Employment

  

Citizenship

1. Steven Presley    Chairman of the Board, Chief Executive Officer and President, NIMCO    US
2. Giulio Gerardo    Director and Chief Financial Officer, NIMCO    Italian
3. Alan Pasetsky    Vice President and Assistant Treasurer, Taxes, NIMCO    US
4. Dan Nugent    Chief Legal Officer and General Counsel, NIMCO    US
5. Alexandra Neely    Treasurer, NIMCO    US
6. Kathleen Carl    Vice President, NIMCO    US
7. Michael Prewitt    Secretary (non Director), NIMCO    US
8. James Parent    Head of Tax, NIMCO    US
9. Rui Barbas    Director, NIMCO    Portugal

Nestlé US Holdco, Inc.

Nestlé US Holdco, Inc. is organized under the laws of the State of Delaware with its principal business address at 1812 North Moore Street, Arlington, VA 22209. Nestlé US Holdco, Inc. is a wholly-owned subsidiary of Société des Produits Nestlé S.A. The name, present principal employment and citizenship of each director and executive officer of Nestlé US Holdco, Inc. is set forth below.

 

1


Name

  

Present Principal Employment

  

Citizenship

1. Steven Presley    Chairman of the Board, Chief Executive Officer and President, Nestlé US Holdco, Inc.    US
2. Giulio Gerardo    Chief Financial Officer, Nestlé US Holdco, Inc.    Italian
3. Alexandra Neely    Treasurer, Nestlé US Holdco, Inc.    US
4. Michael Prewitt    Secretary, Nestlé US Holdco, Inc.    US
5. James Parent    Vice President and Assistant Treasurer, Taxes, Nestlé US Holdco, Inc.    US
6. Daniel Nugent    Director, Nestlé US Holdco, Inc.    US

Société des Produits Nestlé S.A.

Société des Produits Nestlé S.A. is organized under the laws of Switzerland with its principal business address at Avenue Nestlé 55, CH-1800 Vevey Switzerland. Société des Produits Nestlé S.A. is a wholly-owned subsidiary of Nestlé S.A. The name, present principal employment and citizenship of each director and executive officer of Société des Produits Nestlé S.A. is set forth below.

 

Name

  

Present Principal Employment

  

Citizenship

1. Stefan Helfenstein    Chairman of the Board, Société des Produits Nestlé S.A.    Swiss
2. Michèle Burger    Director, Société des Produits Nestlé S.A.    Swiss
3. José Checa Cortés    Director, Société des Produits Nestlé S.A.    Spanish
4. Thomas Hauser    Director, Société des Produits Nestlé S.A.    Swiss
5. Blaise Revillard    Director, Société des Produits Nestlé S.A.    French
6. Philippe Vossen    Director, Société des Produits Nestlé S.A.    Belgian
7. Silvan Jampen    Secretary (non Director), Société des Produits Nestlé S.A.    Swiss
8. Michel Gardet    Senior Vice President, Société des Produits Nestlé S.A.    French
9. Olivier Ballevre    Vice President, Société des Produits Nestlé S.A.    French
10. Trevor Douglas Brown    Vice President, Société des Produits Nestlé S.A.    Swiss
11. Harold Humbert    Vice President, Société des Produits Nestlé S.A.    French
12. Claudio Kuoni    Vice President, Société des Produits Nestlé S.A.    Swiss
13. Damien Tissot    Vice President, Société des Produits Nestlé S.A.    French

Nestlé S.A.

Nestlé S.A. is a corporation organized under the laws of Switzerland with its principal business address at Avenue Nestlé 55, CH-1800, Vevey Switzerland. The name, present principal employment and citizenship of each director and executive officer of Nestlé is set forth below.


Name

  

Present Principal Employment

  

Citizenship

1. Paul Bulcke    Non-Executive Director, Chairman, Nestlé S.A.; Vice-Chairman, L’Oréal S.A.; Board member, Roche Holding Ltd.    Belgian/Swiss
2. Ulf Mark Schneider    Chief Executive Officer, Board member, Nestlé S.A.    German/US
3. Henri de Castries    Non-Executive Director; Vice Chairman, Lead Independent Director, Nestlé S.A.; Board member, HSBC Holdings plc, Argus Media    French
4. Renato Fassbind    Non-Executive Director; Vice Chairman and Lead Independent Director, Swiss Re AG; Board member, Kühne+Nagel International AG    Swiss
5. Ann M. Veneman    Non-Executive Director; Board member, the Global Health Innovative Technology Fund, Advisory Board member JUST Capital, the Clinton Health Access Initiative, the Full Harvest Technologies, Inc.    US
6. Eva Cheng    Non-Executive Director; Board member, Haier Electronics Group Co. Ltd.    Chinese
7. Patrick Aebischer    Non-Executive Director; President Emeritus of Institute EPFL; Board member: Logitech International S.A.; Chairman: Novartis Bioventures AG    Swiss
8. Ursula M. Burns    Non-Executive Director; Board member: Exxon Mobil Corporation, Uber Technologies Inc.; Trustee, Ford Foundation    US
9. Kasper Rorsted    Non-Executive Director; CEO, adidas AG    Danish
10. Pablo Isla    Non-Executive Director; Chairman and CEO, Inditex S.A.    Spanish
11. Kimberly A. Ross    Non-Executive Director; CFO, WeWork    US
12. Dick Boer    Non-Executive Director; Board member, Royal Dutch Shell plc.; Chairman: Advisory Board of G-Star RAW CV, Rijksmuseum Fonds    Netherlands
13. Dinesh Paliwal    Non-Executive Director; Senior Advisor to the Board and CEO, Harman International Industries Inc. Board member, Bristol-Myers Squibb, Raytheon Company; Member, U.S.-India Business Council    US/Indian Overseas Citizenship
14. Hanne Jimenez de Mora    Non-Executive Director; Board member: AB Volvo, Outotec Oyj; Vice-chair: IMD Business School    Swiss


15. Laurent Freixe    Executive Vice President: Chief Executive Officer: Zone Americas    French
16. Chris Johnson    Executive Vice President: Chief Executive Officer: Zone Asia, Oceania and sub-Saharan Africa    US
17. Patrice Bula    Executive Vice President: Strategic Business Units, Marketing, Sales and Nespresso; Board member: Novartis AG, Schindler Holding Ltd.    Swiss
18. Marco Settembri    Executive Vice President: Chief Executive Officer: Zone Europe, Middle East and North Africa    Italian
19. François-Xavier Roger    Executive Vice President: Chief Financial Officer (includes Finance and Control, Tax, Treasury, Investor Relations)    French
20. Magdi Batato    Executive Vice President: Head of Operations; Board member: Carlsberg A/S    Swiss
21. Stefan Palzer   

Executive Vice President: Chief

Technology Officer

   German
22. Béatrice Guillaume-Grabisch    Executive Vice President: Global Head Human Resources & Business Services; Board member: L’Oréal S.A.    French
23. Leanne Geale    Executive Vice President: General Counsel, Corporate Governance and Compliance    Canada
24. Grégory Behar    Deputy Executive Vice President: Chief Executive Officer: Nestlé Health Science    Swiss
25. Sanjay Bahadur    Deputy Executive Vice President: Head of Group Strategy and Business Development    India
26. David P. Frick    Senior Vice President: Secretary to the Board of Directors: Head of Corporate Governance, Compliance and Corporate Services    Swiss
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Nov 2020 to Dec 2020 Click Here for more Seres Therapeutics Charts.
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Dec 2019 to Dec 2020 Click Here for more Seres Therapeutics Charts.